Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through its business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. The company was founded by David J. Sourdive and AndrÃ© Choulika on February 20, 1999 and is headquartered in Paris, France.